CN118206485A - N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 - Google Patents

N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 Download PDF

Info

Publication number
CN118206485A
CN118206485A CN202410205860.2A CN202410205860A CN118206485A CN 118206485 A CN118206485 A CN 118206485A CN 202410205860 A CN202410205860 A CN 202410205860A CN 118206485 A CN118206485 A CN 118206485A
Authority
CN
China
Prior art keywords
crystalline form
crystalline
compound
angles
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410205860.2A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·格罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CN118206485A publication Critical patent/CN118206485A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202410205860.2A 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式 Pending CN118206485A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962851344P 2019-05-22 2019-05-22
US62/851,344 2019-05-22
CN202080045139.1A CN114026071B (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
PCT/US2020/033992 WO2020237047A1 (en) 2019-05-22 2020-05-21 Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080045139.1A Division CN114026071B (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Publications (1)

Publication Number Publication Date
CN118206485A true CN118206485A (zh) 2024-06-18

Family

ID=71016713

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410205860.2A Pending CN118206485A (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
CN202080045139.1A Expired - Fee Related CN114026071B (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080045139.1A Expired - Fee Related CN114026071B (zh) 2019-05-22 2020-05-21 N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式

Country Status (9)

Country Link
US (1) US20230192618A1 (enExample)
EP (1) EP3972957A1 (enExample)
JP (1) JP2022533227A (enExample)
CN (2) CN118206485A (enExample)
AU (1) AU2020280045A1 (enExample)
CA (1) CA3145138A1 (enExample)
IL (1) IL288158A (enExample)
MX (2) MX2021014228A (enExample)
WO (1) WO2020237047A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240107326A (ko) 2021-11-16 2024-07-09 아지오스 파마슈티컬스 아이엔씨. Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011792D1 (de) * 2006-10-27 2011-02-17 Fmc Corp Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
UY36680A (es) * 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) * 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태

Also Published As

Publication number Publication date
MX2024009648A (es) 2024-08-19
CN114026071A (zh) 2022-02-08
JP2022533227A (ja) 2022-07-21
IL288158A (en) 2022-01-01
AU2020280045A1 (en) 2021-12-23
MX2021014228A (es) 2022-02-21
CN114026071B (zh) 2024-03-01
EP3972957A1 (en) 2022-03-30
CA3145138A1 (en) 2020-11-26
US20230192618A1 (en) 2023-06-22
WO2020237047A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CN111372920B (zh) N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶形式
CN114026071B (zh) N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
US20230172926A1 (en) THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCER
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EA042666B1 (ru) Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида
WO2026012350A1 (zh) 色烯酮类化合物的应用
HK40108228A (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination